Prevention and treatment of liver allograft antibody-mediated rejection and the role of the 'two-hit hypothesis'

Current Opinion in Organ Transplantation

Volumn 21, Issue 2, 2016, Pages 209-218

  Kim, Peter T W ^a   Demetris, Anthony J ^b   O'Leary, Jacqueline G ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

acute antibody mediated rejection; chronic antibody mediated rejection; donor specific antibodies; outcomes; rejection

Indexed keywords

ALEMTUZUMAB; ALLOANTIBODY; BORTEZOMIB; COMPLEMENT COMPONENT C4D; DONOR SPECIFIC ALLOANTIBODY; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN; METHYLPREDNISOLONE SODIUM SUCCINATE; OKT 3; PROTEASOME INHIBITOR; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; HLA ANTIGEN;

ACUTE GRAFT REJECTION; ALGORITHM; ANTIBODY MEDIATED REJECTION; BLOOD TRANSFUSION; CELLULAR IMMUNITY; CHRONIC GRAFT REJECTION; CHRONIC INFLAMMATION; CLINICAL FEATURE; DILUTION; FLUORESCENCE ANALYSIS; HUMAN; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MEDICATION COMPLIANCE; MICROANGIOPATHY; NONHUMAN; PLASMAPHERESIS; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; ALLOTRANSPLANTATION; GRAFT REJECTION; IMMUNOLOGY;

GRAFT REJECTION; HLA ANTIGENS; HUMANS; ISOANTIBODIES; LIVER TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84960433303     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000275     Document Type: Review

References (94)

1. Smith RN, Colvin RB. Chronic alloantibody mediated rejection. Seminars in immunology 2012; 24: 115-121.
2. Oleary JG, Michelle Shiller S, Bellamy C, et al. Acute liver allograft antibodymediated rejection: an inter-institutional study of significant histopathological features. Liver Transpl 2014; 20: 1244-1255.
3. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2011; 30: 252-269.
4. Oleary JG, Demetris AJ, Friedman LS, et al. The role of donor-specific HLA alloantibodies in liver transplantation. Am J Transplant 2014; 14: 779-787.
5. Oleary JG, Kaneku H, Demetris AJ, et al. Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss. Liver Transpl 2014; 20: 218-227.
6. Taner T, Gandhi MJ, Sanderson SO, et al. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant 2012; 12: 1504-1510.
7. Oleary JG, Kaneku H, Jennings LW, et al. Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation. Liver Transpl 2013; 19: 973-980.
8. Musat AI, Pigott CM, Ellis TM, et al. Pretransplant donor-specific anti-HLA antibodies as predictors of early allograft rejection in ABO-compatible liver transplantation. Liver Transpl 2013; 19: 1132-1141.
9. Kozlowski T, Rubinas T, Nickeleit V, et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donorspecific antibodies. Liver Transpl 2011; 17: 357-368.
10. Gugenheim J, Amorosa L, Gigou M, et al. Specific absorption of lymphocytotoxic alloantibodies by the liver in inbred rats. Transplantation 1990; 50: 309-313.
11. Astarcioglu I, Cursio R, Reynes M, Gugenheim J. Increased risk of antibodymediated rejection of reduced-size liver allografts. J Surg Res 1999; 87: 258-262.
12. Demetris AJ, Isse K. Tissue biopsy monitoring of operational tolerance in liver allograft recipients. Curr Opin Organ Transplant 2013; 18: 345-353.
13. Liu X, Xu J, Brenner DA, Kisseleva T. Reversibility of liver fibrosis and inactivation of fibrogenic myofibroblasts. Curr Pathobiol Rep 2013; 1: 209-214.
14. Del Bello A, Congy-Jolivet N, Muscari F, et al. Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients. Am J Transplant 2014; 14: 867-875.
15. Demetris AJ, Nakamura K, Yagihashi A, et al A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology 1992; 16: 671-681.
16. Lunz J, Ruppert KM, Cajaiba MM, et al. Re-examination of the lymphocytotoxic crossmatch in liver transplantation: can C4d stains help in monitoring?. Am J Transplant 2012; 12: 171-182.
17. Demetris AJ, Jaffe R, Tzakis A, et al. Antibody-mediated rejection of human orthotopic liver allografts A study of liver transplantation across ABO blood group barriers. Am J Pathol 1988; 132: 489-502.
18. Demetris AJ, Murase N, Nakamura K, et al. Immunopathology of antibodies as effectors of orthotopic liver allograft rejection. Semin Liver Dis 1992; 12: 51-59.
19. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl 2012; 18: 1333-1342.
20. Girnita A, Mazariegos GV, Castellaneta A, et al. Liver transplant recipients weaned off immunosuppression lack circulating donor-specific antibodies. Hum Immunol 2010; 71: 274-276.
21. Markiewicz-Kijewska M, Kalicinski P, Kluge P, et al. Immunological factors and liver fibrosis in pediatric liver transplant recipients. Ann Transplant 2015; 20: 279-284.
22. Wozniak LJ, Hickey MJ, Venick RS, et al. Donor-specific HLA antibodies are associated with late allograft dysfunction after pediatric liver transplantation. Transplantation 2015; 99: 1416-1422.
23. Oleary JG, Cai J, Freeman R, et al. Proposed diagnostic criteria for chronic antibody-mediated rejection in liver allografts. Am J Transplant 2016; 16: 603-614.
24. Kheradmand T, Anthony TL, Harland RC, et al. Antibody-mediated rejection in ABO compatible husband to wife living donor liver transplant and review of the literature. Hum Immunol 2014; 75: 578-583.
25. Paterno F, Shiller M, Tillery G, et al. Bortezomib for acute antibody-mediated rejection in liver transplantation. Am J Transplant 2012; 12: 2526-2531.
26. Watson R, Kozlowski T, Nickeleit V, et al. Isolated donor specific alloantibodymediated rejection after ABO compatible liver transplantation. Am J Transplant 2006; 6: 3022-3029.
27. Rostron A, Carter V, Mutunga M, et al A case of acute humoral rejection in liver transplantation: successful treatment with plasmapheresis and mycophenolate mofetil. Transpl Int 2005; 18: 1298-1301.
28. Kamar N, Lavayssiere L, Muscari F, et al. Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantation. World J Gastroenterol 2009; 15: 3426-3430.
29. Farkash EA, Colvin RB. Diagnostic challenges in chronic antibody-mediated rejection. Nat Rev Nephrol 2012; 8: 255-257.
30. Manez R, Kelly RH, Kobayashi M, et al. Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: studies toward further defining their significance. Hepatology 1995; 21: 1345-1352.
31. Nakamura K, Yagihashi A, Iwaki Y, et al. The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis. Transplant Proc 1991; 23: 3021-3022.
32. Neau-Cransac M, Le Bail B, Guidicelli G, et al. Evolution of serum and intragraft donor-specific anti-HLA antibodies in a patient with two consecutive liver transplantations. Transpl Immunol 2015; 33: 58-62.
33. Kubal CA, Mangus RS, Saxena R, et al. Crossmatch-positive liver transplantation in patients receiving thymoglobulin-rituximab induction. Transplantation 2014; 97: 56-63.
34. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658-663.
35. Musat AI, Agni RM, Wai PY, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11: 500-510.
36. Ali S, Ormsby A, Shah V, et al. Significance of complement split product C4d in ABO-compatible liver allograft: diagnosing utility in acute antibody mediated rejection. Transpl Immunol 2012; 26: 62-69.
37. Aguilera I, Sousa JM, Gavilan F, et al. Complement component 4d immunostaining in liver allografts of patients with de novo immune hepatitis. Liver Transpl 2011; 17: 779-788.
38. Bouron-Dal Soglio D, Rougemont AL, Herzog D, et al. An immunohistochemical evaluation of C4d deposition in pediatric inflammatory liver diseases. Hum Pathol 2008; 39: 1103-1110.
39. Jain A, Ryan C, Mohanka R, et al. Characterization of CD4, CD8, CD56 positive lymphocytes and C4d deposits to distinguish acute cellular rejection from recurrent hepatitis C in postliver transplant biopsies. Clin Transplant 2006; 20: 624-633.
40. Bellamy CO, Herriot MM, Harrison DJ, Bathgate AJ. C4d immunopositivity is uncommon in ABO-compatible liver allografts, but correlates partially with lymphocytotoxic antibody status. Histopathology 2007; 50: 739-749.
41. Kozlowski T, Andreoni K, Schmitz J, et al. Sinusoidal C4d deposits in liver allografts indicate an antibody-mediated response: diagnostic considerations in the evaluation of liver allografts. Liver Transpl 2012; 18: 641-658.
42. Sakashita H, Haga H, Ashihara E, et al. Significance of C4d staining in ABOidentical/compatible liver transplantation. Mod Pathol 2007; 20: 676-684.
43. Troxell ML, Higgins JP, Kambham N. Evaluation of C4d staining in liver and small intestine allografts. Arch Pathol Lab Med 2006; 130: 1489-1496.
44. Ruiz R, Tomiyama K, Campsen J, et al. Implications of a positive crossmatch in liver transplantation: a 20-year review. Liver Transpl 2012; 18: 455-460.
45. Castillo-Rama M, Castro MJ, Bernardo I, et al. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: role of human leukocyte antigen compatibility. Liver Transpl 2008; 14: 554-562.
46. Demetris AJ, Zeevi A, OLeary JG. ABO-compatible liver allograft antibodymediated rejection: an update. Curr Opin Organ Transplant 2015; 20: 314-324.
47. Iacob S, Cicinnati VR, Lindemann M, et al. Donor-Specific Anti-HLA Antibodies and Endothelial C4d Deposition-Association With Chronic Liver Allograft Failure. Transplantation 2015; 99: 1869-1875.
48. Demetris AJ, Markus BH, Burnham J, et al. Antibody deposition in liver allografts with chronic rejection. Transplant Proc 1987; 19 (4 Suppl 5): 121-125.
49. OLeary JG, Kaneku H, Susskind BM, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. Am J Transplant 2011; 11: 1868-1876.
50. Woodle ES, Perdrizet GA, So SK, et al. FK 506 rescue therapy for hepatic allograft rejection: experience with an aggressive approach. Clin Transplant 1995; 9: 45-52.
51. Wilson CH, Agarwal K, Carter V, et al. Late humoral rejection in a compliant ABO-compatible liver transplant recipient. Transplantation 2006; 82: 988-989.
52. Schadde E, dAlessandro AM, Musat AI, et al. Donor-specific HLA-Antibodymediated humoral rejection in a liver transplant recipient fully reversed with plasmapheresis and immunoglobulin. Clin Transpl 2006; 479-482.
53. Yamada N, Urahashi T, Ihara Y, et al. Veno-occlusive disease/sinusoidal obstruction syndrome associated with potential antibody-mediated rejection after pediatric living donor liver transplantation: a case report. Transplant Proc 2012; 44: 810-813.
54. Gillet-Hladky S, de Carvalho CM, Bernaud J, et al. Rabbit antithymocyte globulin inhibits monocyte-derived dendritic cells maturation in vitro and polarizes monocyte-derived dendritic cells towards tolerogenic dendritic cells expressing indoleamine 2, 3-dioxygenase. Transplantation 2006; 82: 965-974.
55. Stauch D, Dernier A, Sarmiento Marchese E, et al. Targeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: similar effects independent of specificity. PLoS One 2009; 4: e4709.
56. Roberts DM, Jiang SH, Chadban SJ. The treatment of acute antibodymediated rejection in kidney transplant recipients-A systematic review. Transplantation 2012; 94: 775-783.
57. Jordan SC, Toyoda M, Kahwaji J, Vo AA. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients. Am J Transplant 2011; 11: 196-202.
58. Crespo M, Pascual M, Tolkoff-Rubin N, et al. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 2001; 71: 652-658.
59. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887-895.
60. Pascual M, Saidman S, Tolkoff-Rubin N, et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 1998; 66: 1460-1464.
61. Jordan SC, Quartel AW, Czer LS, et al. Posttransplant therapy using highdose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998; 66: 800-805.
62. Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9: 1099-1107.
63. White NB, Greenstein SM, Cantafio AW, et al. Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation 2004; 78: 772-774.
64. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- And cell-mediated acute rejection. Transplantation 2008; 86: 1754-1761.
65. Flechner SM, Fatica R, Askar M, et al. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation 2010; 90: 1486-1492.
66. Walsh RC, Everly JJ, Brailey P, et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010; 89: 277-284.
67. Thomas PG, Ishihara K, Vaidya S, Gugliuzza KK. Campath and renal transplant rejection. Clin Transplant 2004; 18: 759-761.
68. Csapo Z, Benavides-Viveros C, Podder H, et al. Campath-1H as rescue therapy for the treatment of acute rejection in kidney transplant patients. Transplant Proc 2005; 37: 2032-2036.
69. Jirasiritham S, Khunprakant R, Techawathanawanna N, et al. Treatment of simultaneous acute antibody-mediated rejection and acute cellular rejection with alemtuzumab in kidney transplantation: a case report. Transplant Proc 2010; 42: 987-989.
70. Cossburn MD, Harding K, Ingram G, et al. Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis. Neurology 2013; 80: 55-61.
71. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368: 11-21.
72. De Pietri L, Bianchini M, Montalti R, et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy A randomized controlled trial. Hepatology 2016; 63: 566-573.
73. Rahimi RS, OLeary JG. Transfusing common sense instead of blood products into coagulation testing in patients with cirrhosis: overtreatment not equal safety. Hepatology 2016; 63: 368-370.
74. OLeary JG, Gebel HM, Ruiz R, et al. Class II alloantibody and mortality in simultaneous liver-kidney transplantation. Am J Transplant 2013; 13: 954-960.
75. Dar W, Agarwal A, Watkins C, et al. Donor-directed MHC class I antibody is preferentially cleared from sensitized recipients of combined liver/kidney transplants. Am J Transplant 2011; 11: 841-847.
76. Clatworthy MR, Watson CJ, Plotnek G, et al. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009; 360: 2683-2685.
77. OLeary JG, Samaniego M, Crespo M, et al. The influence of immunosuppressive agents on the risk of de novo donor-specific HLA antibody production in solid organ transplant recipients. Transplantation 2015; 100: 39-53.
78. Donaldson PT, Alexander GJ, OGrady J, et al. Evidence for an immune response to HLA class I antigens in the vanishing-bileduct syndrome after liver transplantation. Lancet 1987; 1: 945-951.
79. Ludwig J, Wiesner RH, Batts KP, et al. The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation. Hepatology 1987; 7: 476-483.
80. Batts KP, Moore SB, Perkins JD, et al. Influence of positive lymphocyte crossmatch and HLA mismatching on vanishing bile duct syndrome in human liver allografts. Transplantation 1988; 45: 376-379.
81. Takaya S, Jain A, Yagihashi A, et al. Increased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts. Transplant Proc 1999; 31: 2028-2031.
82. Ohe H, Uchida Y, Yoshizawa A, et al. Association of antihuman leukocyte antigen and antiangiotensin II type 1 receptor antibodies with liver allograft fibrosis after immunosuppression withdrawal. Transplantation 2014; 98: 1105-1111.
83. OLeary JG, Kaneku H, Jennings L, et al. Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients. Liver Transpl 2014; 20: 655-663.
84. Feng S, Ekong UD, Lobritto SJ, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 2012; 307: 283-293.
85. Feng S, Demetris AJ, Isse K, et al. Serum and tissue DSA subclass, stellate and endothelial phenotype monitoring in ITN029ST tolerant pediatric liver transplant recipients over 5 years of follow-up. Liver Transpl 2014; 20: S117.
86. Kaneku H, OLeary JG, Banuelos N, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant 2013; 13: 1541-1548.
87. Sher LS, Cosenza CA, Michel J, et al. Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation: a report of the U.S. Multicenter Liver Study Group. Transplantation 1997; 64: 258-263.
88. Thinesh L. Krishnamoorthy JM-K, James Hodson, Bridget K Gunson, et al. Long term low dose steroid triple immunosuppression in post transplant autoimmune hepatitis patients reduces recurrent disease without increasing mortality. Transplantation 2015; 99: 90.
89. Villamil FG, Gadano AC, Zingale F, et al. Fibrosis progression in maintenance liver transplant patients with hepatitis C recurrence: a randomised study of everolimus vs. calcineurin inhibitors. Liver Int 2014; 34: 1513-1521.
90. McKenna GJ, Trotter JF, Klintmalm E, et al. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am J Transplant 2011; 11: 2379-2387.
91. Vincenti F, Charpentier B, Vanrenterghem Y, et al A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
92. Pestana JO, Grinyo JM, Vanrenterghem Y, et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012; 12: 630-639.
93. Lee SJ, Qin H, Benveniste EN. The IFN-gamma-induced transcriptional program of the CIITA gene is inhibited by statins. Eur J Immunol 2008; 38: 2325-2336.
94. Muczynski KA, Ekle DM, Coder DM, Anderson SK. Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: characterization, isolation, and regulation of MHC class II expression. J Am Soc Nephrol 2003; 14: 1336-1348.